ArticleThe oncologist2026

Minimal residual disease assessment through ctDNA facilitates tailored immunotherapy in MSI-high, NTRK1-fusion pancreatic adenocarcinoma.

Sarah Rohlfing et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.